Compare Recursion Pharmaceuticals Inc (RXRX) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Snap Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.35 (market cap $2.14B), while Snap Inc trades at $6.24 (market cap $9.83B). The key difference: Snap Inc is far larger — about 4.6× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 28,532,342). Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Snap Inc for 68 Days on average.
| RXRX | SNAP | |
|---|---|---|
Market Cap | $2.14B | $9.83B |
Volume | 30,789,535 | 28,532,342 |
Sector | Health | Media |
52-Week High | $6.79 | $9.09 |
52-Week Low | $2.84 | $3.93 |
Typical Hold Time | 23 Days | 68 Days |
Enterprise Value | $1.66B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Snap Inc. (SNAP) trades at $6.235, up 7.31% with bullish technical signals and strong institutional interest. The company shows improving fundamentals with revenue growth from $5.4B to $5.9B (2024-2025) and narrowing losses. Recent AI partnerships with Nvidia and Salesforce for SPECS glasses highlight innovation efforts. Operating cash flow improved to $656M in 2025, though net income remains negative at -$460M.
While Snap demonstrates operational momentum and analyst support (38% buy ratings), significant risks persist including regulatory pressures, intense competition, and continued profitability challenges. The stock's current valuation at 1.55x sales appears reasonable given growth trajectory, but investors should weigh improving fundamentals against persistent net losses and high debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
